← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Abbratech, Inc.
Branford, CT
$7,341,646
Total funding
8
Grants
Funding over time
peak $3.4M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$7,341,646 · 8
By mechanism
R44$6,453,596 · 5
R43$888,050 · 3
Investigators at Abbratech, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.$1,121,971
R44 · FY2023 · GM
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.$1,121,971
R44 · FY2024 · GM
Platform for the High Throughput Generation and Validation of Affinity Reagents$1,080,240
R44 · FY2024 · GM
Platform for the High Throughput Generation and Validation of Affinity Reagents$1,080,240
R44 · FY2023 · GM
Structure-guided neutralizing antibodies developed using EpiVolve technology$995,774
R44 · FY2024 · AI
DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs$551,373
R44 · FY2025 · GM
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. I. survey of existing antibodies, and II. development of method improvements$339,150
R43 · FY2022 · GM
Structure-guided neutralizing antibodies developed using EpiVolve technology$296,100
R44 · FY2023 · AI
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy$295,460
R43 · FY2023 · GM
Method for the isolation of antibodies with functional activity against cell surface targets$253,440
R43 · FY2022 · AI
DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs$205,926
R44 · FY2024 · GM
A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D$1
R44 · FY2025 · GM